Not that Fibonacci is any authoritative source, but a Price Target of $1.50 does not mean our pps would go to that immediately, it means that is what some analyst feels it has the potential to move toward over a period of time.
I have to agree with Risk. The right news, the right catalyst, the right data and the right analyst hopping on board could take Amarantus to new heights. But can Gerald get er done? That's the question.
fibby has stated a lot of things that haven't come to fruition. But, anything that can get a big pharma interested is always a good thing. For AMBS' sake, better hope the data is stellar. The company needs to start actually showing it can create shareholder value instead of just talking about it. Points to Gerarld.